Total Payments
$433,854
2024 Payments
$58,003
Companies
36
Transactions
978
Medicare Patients
4,803
Medicare Billing
$950,501
Payment Breakdown by Category
Other$301,701 (69.5%)
Travel$83,169 (19.2%)
Consulting$27,781 (6.4%)
Food & Beverage$19,161 (4.4%)
Education$2,042 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $259,522 | 165 | 59.8% |
| Travel and Lodging | $83,169 | 184 | 19.2% |
| Honoraria | $34,480 | 18 | 7.9% |
| Consulting Fee | $27,781 | 24 | 6.4% |
| Food and Beverage | $19,161 | 569 | 4.4% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $7,700 | 2 | 1.8% |
| Education | $2,042 | 16 | 0.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Theravance Biopharma, Inc. | $77,998 | 95 | $0 (2018) |
| Ferring Pharmaceuticals Inc. | $67,354 | 124 | $0 (2024) |
| The Medicines Company | $51,845 | 96 | $0 (2017) |
| Astellas Pharma US Inc | $51,114 | 123 | $0 (2024) |
| PFIZER INC. | $51,083 | 28 | $0 (2024) |
| Allergan, Inc. | $34,469 | 101 | $0 (2020) |
| Melinta Therapeutics, LLC | $33,093 | 79 | $0 (2024) |
| Cumberland Pharmaceuticals, Inc. | $20,791 | 35 | $0 (2024) |
| Merck Sharp & Dohme LLC | $15,650 | 68 | $0 (2024) |
| Oxford Immunotec Inc. | $9,826 | 8 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $58,003 | 83 | PFIZER INC. ($39,274) |
| 2023 | $66,877 | 143 | Ferring Pharmaceuticals Inc. ($40,639) |
| 2022 | $20,652 | 71 | Astellas Pharma US Inc ($11,189) |
| 2021 | $19,628 | 83 | Ferring Pharmaceuticals Inc. ($14,950) |
| 2020 | $7,520 | 62 | Allergan, Inc. ($3,210) |
| 2019 | $38,719 | 119 | Melinta Therapeutics, Inc. ($11,209) |
| 2018 | $85,425 | 140 | Theravance Biopharma, Inc. ($44,461) |
| 2017 | $137,030 | 277 | The Medicines Company ($51,845) |
All Payment Transactions
978 individual payment records from CMS Open Payments — Page 1 of 40
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $318.75 | General |
| Category: ANTIFUNGALS | ||||||
| 12/11/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), ZERBAXA | Food and Beverage | In-kind items and services | $23.47 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/09/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $850.00 | General |
| Category: Infectious Diseases | ||||||
| 12/06/2024 | PFIZER INC. | PAXLOVID (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,525.00 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 12/05/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $15.98 | General |
| Category: Infectious Diseases | ||||||
| 11/20/2024 | ABBVIE INC. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $23.54 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/19/2024 | PFIZER INC. | PAXLOVID (Drug) | Travel and Lodging | In-kind items and services | $71.77 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 11/13/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $25.01 | General |
| Category: VIROLOGY | ||||||
| 11/04/2024 | PFIZER INC. | PAXLOVID (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,300.00 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 10/31/2024 | PFIZER INC. | PAXLOVID (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,800.00 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 10/31/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Consulting Fee | Cash or cash equivalent | $513.00 | General |
| Category: Infectious Diseases | ||||||
| 10/31/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $21.76 | General |
| Category: Respiratory | ||||||
| 10/23/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), ZERBAXA | Food and Beverage | In-kind items and services | $23.28 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/18/2024 | PFIZER INC. | PAXLOVID (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 10/18/2024 | PFIZER INC. | PAXLOVID (Drug) | Travel and Lodging | In-kind items and services | $1,235.91 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 10/18/2024 | PFIZER INC. | PAXLOVID (Drug) | Travel and Lodging | In-kind items and services | $928.44 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 10/18/2024 | PFIZER INC. | PAXLOVID (Drug) | Travel and Lodging | In-kind items and services | $530.18 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 10/16/2024 | PFIZER INC. | PAXLOVID (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 10/16/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa, Orbactiv | Food and Beverage | In-kind items and services | $22.96 | General |
| Category: ANTIFUNGALS | ||||||
| 10/10/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $15.98 | General |
| Category: Infectious Diseases | ||||||
| 10/09/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $18.12 | General |
| Category: VIROLOGY | ||||||
| 10/03/2024 | PFIZER INC. | PAXLOVID (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 10/03/2024 | PFIZER INC. | PAXLOVID (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 10/02/2024 | La Jolla Pharmaceutical Company | XACDURO (Drug) | Food and Beverage | In-kind items and services | $17.10 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/25/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), ZERBAXA | Food and Beverage | In-kind items and services | $19.97 | General |
| Category: INFECTIOUS DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 927 | 2,634 | $292,870 | $184,644 |
| 2022 | 4 | 1,051 | 3,049 | $330,537 | $206,604 |
| 2021 | 5 | 1,146 | 3,209 | $354,376 | $218,534 |
| 2020 | 6 | 1,679 | 5,312 | $566,145 | $340,719 |
Total Patients
4,803
Total Services
14,204
Medicare Billing
$950,501
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 321 | 1,705 | $148,335 | $98,157 | 66.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 246 | 527 | $71,285 | $45,779 | 64.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 262 | 303 | $51,650 | $28,172 | 54.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 70 | 70 | $14,350 | $8,183 | 57.0% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 28 | 29 | $7,250 | $4,353 | 60.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 405 | 2,086 | $181,482 | $114,261 | 63.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 240 | 513 | $69,955 | $44,774 | 64.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 339 | 383 | $65,355 | $39,584 | 60.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 67 | 67 | $13,745 | $7,984 | 58.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 412 | 2,153 | $187,311 | $119,488 | 63.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 266 | 552 | $74,870 | $43,988 | 58.8% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 341 | 376 | $64,200 | $39,806 | 62.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 89 | 89 | $18,245 | $9,340 | 51.2% |
| 99496 | Transitional care management services, highly complexity, requiring face-to-face visits within 7 days of discharge | Office | 2021 | 38 | 39 | $9,750 | $5,913 | 60.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 665 | 3,830 | $333,210 | $214,208 | 64.3% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 546 | 625 | $106,460 | $66,118 | 62.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 330 | 719 | $97,205 | $45,892 | 47.2% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 74 | 74 | $15,070 | $7,431 | 49.3% |
| 99496 | Transitional care management services, highly complexity, requiring face-to-face visits within 7 days of discharge | Office | 2020 | 48 | 48 | $12,000 | $6,133 | 51.1% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 16 | 16 | $2,200 | $936.21 | 42.6% |
About Dr. Ali Hassoun, MD
Dr. Ali Hassoun, MD is a Infectious Disease healthcare provider based in Huntsville, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/17/2005. The National Provider Identifier (NPI) number assigned to this provider is 1063404978.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ali Hassoun, MD has received a total of $433,854 in payments from pharmaceutical and medical device companies, with $58,003 received in 2024. These payments were reported across 978 transactions from 36 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($259,522).
As a Medicare-enrolled provider, Hassoun has provided services to 4,803 Medicare beneficiaries, totaling 14,204 services with total Medicare billing of $950,501. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Huntsville, AL
- Active Since 08/17/2005
- Last Updated 10/10/2012
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1063404978
Products in Payments
- VIBATIV (Drug) $82,979
- PAXLOVID (Drug) $51,083
- REBYOTA (Biological) $44,730
- AVYCAZ (Drug) $24,799
- MINOCIN IV (Drug) $22,857
- Cresemba (Drug) $17,417
- CRESEMBA (Drug) $17,253
- VABOMERE (Drug) $17,040
- DIFICID (Drug) $15,156
- Vibativ (Drug) $12,046
- Rezzayo (Drug) $10,840
- Vabomere (Drug) $9,936
- TSPOT TB TEST (Device) $9,826
- DALVANCE (Drug) $9,442
- Xerava (Drug) $8,494
- ORBACTIV (Drug) $7,715
- Orbactiv (Drug) $7,520
- Genvoya (Drug) $4,885
- Fetroja (Drug) $2,660
- Baxdela (Drug) $2,562
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Huntsville
Dr. Scott Parker, Md, MD
Infectious Disease — Payments: $9,823
Infectious Disease $9,823
Mrs. Hafsa Siddiqui, M.d, M.D
Infectious Disease — Payments: $3,408
Infectious Disease $3,408
Dr. Andres Gutierrez Ordonez, M.d, M.D
Infectious Disease — Payments: $1,988
Infectious Disease $1,988
Ingrid Roig, M.d, M.D
Infectious Disease — Payments: $593.53
Infectious Disease $593.53
Dr. Tommy Parraga, M.d, M.D
Infectious Disease — Payments: $576.76
Infectious Disease $576.76
Morgan Scully, M.d, M.D
Infectious Disease — Payments: $430.32
Infectious Disease $430.32